The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No ClinVar Id was directly found from the curated document

  • See Evidence submitted by expert panel for details.

Variant: NM_000212.3:c.652C>T

CA400023445

Gene: ITGB3
Condition: Glanzmann thrombasthenia
Inheritance Mode: Autosomal recessive inheritance
UUID: 87d75123-1e7c-450f-b9fd-e0c2884cee2e

HGVS expressions

NM_000212.3:c.652C>T
NC_000017.11:g.47286297C>T
CM000679.2:g.47286297C>T
NC_000017.10:g.45363663C>T
CM000679.1:g.45363663C>T
NC_000017.9:g.42718662C>T
NG_008332.2:g.37456C>T
ENST00000559488.7:c.652C>T
ENST00000559488.5:c.652C>T
ENST00000560629.1:n.617C>T
ENST00000571680.1:c.652C>T
NM_000212.2:c.652C>T

Uncertain Significance

Met criteria codes 4
PP3 PM3_Supporting PM2_Supporting PP4_Moderate

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Platelet Disorders VCEP
The ITGB3 missense variant NM_000212.3:c.652C>T replaces the histidine residue with a tyrosine residue (p.His218Tyr). This variant has been observed in homozygosity in one individual with a phenotype specific for Glanzmann's thrombasthenia (GT) (GT17, PMID: 16463284). This variant is absent from population databases and the in silico meta-predictor REVEL score for this variant is 0.938, exceeding the VCEP-established threshold of ≥0.7 and suggestive of a damaging effect on protein function. In summary, this variant is of uncertain significance and lacks sufficient evidence to be classified as pathogenic or benign for GT. GT-specific criteria applied: PP4_moderate, PM2_supporting, PM3_supporting, and PP3.
Met criteria codes
PP3
This variant has a REVEL score of 0.938, exceeding the VCEP-established threshold of ≥0.7 and meeting the criteria for PP3.
PM3_Supporting
This variant was reported in homozygosity in one individual (GT17 in PMID: 16463284), sufficient to apply PM3_Supporting.
PM2_Supporting
This variant is absent from all population cohorts in gnomAD, ExAC, 1000 Genomes, and ESP.
PP4_Moderate
All requirements for PP4_Moderate are met (GT17 in PMID: 16463284): history of bleeding and impaired aggregation to at least two agonists, but normal or only mildly reduced agglutination with ristocetin.
Approved on: 2021-07-14
Published on: 2021-12-23
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.